Possible Role of HER-2 in the Progression of Prostate Cancer from Primary Tumor to Androgen Independence

Murray, Nigel P; Reyes, Eduardo; Fuentealba, Cynthia; Jacob, Omar; Orellana, Nelson

추천

검색

자료유형: 학술저널

저자정보: Murray, Nigel P (Hematology, Medicine, Hospital de Carabineros de Chile, Faculty of Medicine University Finis Terrae) Reyes, Eduardo (Faculty of Medicine University Diego Portales, Hospital DIPRECA) Fuentealba, Cynthia (Urology, Hospital de Carabineros de Chile) Jacob, Omar (Urology, Hospital de Carabineros de Chile) Orellana, Nelson (Urology, Hospital de Carabineros de Chile)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제15호

발행연도: 2015.1

수록면: 6,615 - 6,619 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: The expression of HER-2 in prostate cancer has been linked to disease progression. We analysed the presence of HER-2 expression in primary tumors in men undergoing radical prostatectomy, its association with clinical and pathological findings, and its expression in secondary circulating prostate cells (CPCs) during follow up, as well as links with biochemical failure and the effects of androgen blockade. Materials and Methods: Consecutive men undergoing radical prostatectomy for histologically confirmed prostate cancer were analyzed. HER-2 expression in the primary tumor was assessed using the HercepTest(R), CPCs were identified from blood samples using standard immunocytochemistry with anti-PSA and positive samples with the HercepTest(R) to determine HER-2 expression. The influence of HER-2 expression on the frequency of biochemical failure and effects of androgen blockade was determined. Results: 144 men with a mean age of $64.8{\pm}10.3$ years participated, with a median follow up of 8.2 years. HER-2 was expressed in 20.8% of primary tumors; it was associated with vascular infiltration and older age, but not with other clinical pathological findings. Some 40.3% of men had secondary CPCs detected, of which 38% expressed HER-2. Men CPC (+) had a higher frequency of biochemical failure, but there was no difference in HER-2 expression of CPCs with the frequency of biochemical failure. After androgen blockade, men with HER-2 (+) positive secondary CPCs had a higher frequency of disease progression to castrate resistant disease. Conclusions: HER-2 plays a dual role in the progression of prostate cancer; firstly it may increase the potential of tumor cells to disseminate from the primary tumor via the blood by increasing vascular infiltration. In the presence of androgens, there is no survival advantage of expressing HER-2, but once biochemical failure has occurred and androgen blockade started, HER-2 positive cells are resistant to treatment, survive and grow leading to castration resistant disease.

#Prostate cancer #HER-2 #circulating prostate cells #biochemical failure #castrate resistant

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

Murray, Nigel P

소속기관 Hematology, Medicine, Hospital de Carabineros de Chile, Faculty of Medicine University Finis Terrae